Jubilant Pharmo

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE700A01033
NSEID: JUBLPHARMA
BSEID: 530019

INR

1,066.60

-2.6 (-0.24%)

BSENSE

Dec 05

BSE+NSE Vol: 6.72 k

{
  "main_header": {
    "sid": 525933,
    "name": "Jubilant Pharmo",
    "stock_name": "Jubilant Pharmo",
    "full_name": "Jubilant Pharmova Ltd",
    "name_url": "stocks-analysis/jubilant-pharmo",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,066.60",
    "chg": -2.6,
    "chgp": "-0.24%",
    "dir": -1,
    "prev_price": "1,069.20",
    "mcapval": "16,988.93 Cr",
    "mcap": "Small Cap",
    "scripcode": 530019,
    "symbol": "JUBLPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE700A01033",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "6.72 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jubilant-pharmo-525933-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Jubilant Pharmo technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-jubilant-pharmo-technically-bullish-or-bearish-3745390",
        "imagepath": "",
        "date": "2025-12-04 08:29:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Shift and Current Price Action</strong></p>\n<p>As of 3 December 2025, Jubilant Pharmo's technical trend transitioned from mildly bullish to sideways, signalling a pause in directional momentum. The stock closed at ₹1,077.90, down from the previous close of ₹1,095.45, with intraday trading ranging between ₹1,071.40 and ₹1,098.20. This price action suggests a consolidation phase after recent volatility, with the stock currently trading below its 52-week high of ₹1,263.90 but comfortably above its 52-week low of ₹823.70.</p>\n<p><strong>Mixed Technical Indicators Paint a Complex Picture</strong></p>\n<p>Examining key technical indicators reveals a blend of bearish and mildly bullish signals. The Moving Average Convergence Divergence (MACD) on both weekly and monthly charts remains..."
      },
      {
        "title": "Jubilant Pharmova Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-faces-technical-setback-amid-mixed-momentum-signals-3745426",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/JubilantPharmov_technicaldot_3745426.png",
        "date": "2025-12-04 08:06:47",
        "description": "Jubilant Pharmova’s stock price has experienced a notable shift in momentum, reflecting a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a sideways movement. This development comes amid a backdrop of mixed signals from key technical parameters such as MACD, RSI, moving averages, and Bollinger Bands, highlighting the nuanced market assessment of the pharmaceutical and biotechnology firm."
      },
      {
        "title": "Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-downgraded-to-sell-amid-technical-and-financial-concerns-3745410",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/JubilantPharmov_mojoScore_3745410.png",
        "date": "2025-12-04 08:04:55",
        "description": "Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by flat quarterly financials, subdued technical indicators, and valuation metrics that contrast with its operational performance. The pharmaceutical and biotechnology company’s stock has experienced notable underperformance relative to broader market indices, prompting a revision in its analytical perspective across key parameters including quality, valuation, financial trends, and technical outlook."
      },
      {
        "title": "How has been the historical performance of Jubilant Pharmo?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-jubilant-pharmo-3744700",
        "imagepath": "",
        "date": "2025-12-03 22:45:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Jubilant Pharmo’s net sales have shown a recovery trajectory after a notable dip in 2019. From ₹9,110.82 crores in March 2019, sales declined sharply but then steadily increased to ₹7,234.50 crores by March 2025. This rebound reflects the company’s ability to regain market traction despite earlier challenges. Operating profit margins, excluding other income, peaked at 26.49% in 2020 but experienced a decline to 16.32% by 2025, indicating some margin pressure amid rising costs.</p>\n<p>Profit after tax (PAT) has been more volatile, with a significant loss recorded in 2023 (negative ₹77.13 crores), followed by a strong recovery to ₹836.80 crores in 2025. The PAT margin mirrored this trend, dropping to -1.04% in 2023 before rebounding to 11.63% in..."
      },
      {
        "title": "Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-3732523",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JubilantPharmov_mojoScore_3732523.png",
        "date": "2025-11-27 08:05:05",
        "description": "Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by technical indicators, valuation metrics, financial trends, and quality considerations. While the pharmaceutical company’s stock price shows modest gains, underlying fundamentals and sector comparisons present a complex scenario for investors navigating the Pharmaceuticals & Biotechnology space."
      },
      {
        "title": "Jubilant Pharmova Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-technical-momentum-shifts-amid-mixed-indicator-signals-3727490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JubilantPharmov_technicaldot_3727490.png",
        "date": "2025-11-25 08:06:24",
        "description": "Jubilant Pharmova's stock has exhibited a subtle shift in price momentum, transitioning from a sideways trend to a mildly bullish stance, reflecting nuanced changes in key technical indicators. Despite mixed signals from weekly and monthly charts, the stock’s recent price action and moving averages suggest a cautious optimism within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Jubilant Pharmova Faces Mixed Technical Signals Amid Sideways Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-faces-technical-setback-amid-price-momentum-shift-3723684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JubilantPharmov_technicaldot_3723684.png",
        "date": "2025-11-24 08:02:39",
        "description": "Jubilant Pharmova's stock price has exhibited a shift from a mildly bullish trend to a sideways momentum, reflecting a complex interplay of technical indicators. Recent market data reveals a nuanced picture for this Pharmaceuticals & Biotechnology company, with key metrics such as MACD, RSI, and moving averages signalling a cautious stance for investors."
      },
      {
        "title": "Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-downgraded-to-sell-amid-technical-weakness-and-flat-financials-3723686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JubilantPharmov_mojoScore_3723686.png",
        "date": "2025-11-24 08:02:28",
        "description": "Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by shifts in technical indicators, valuation metrics, financial trends, and overall quality parameters. Despite a discount in valuation relative to peers and a solid institutional investor base, the company’s stock performance and financial growth patterns present a complex scenario for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Jubilant Pharmo falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-jubilant-pharmo-fallingrising-3721883",
        "imagepath": "",
        "date": "2025-11-22 00:33:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Jubilant Pharmova’s shares have been under pressure recently, with a one-week decline of 6.20%, contrasting sharply with the Sensex’s modest gain of 0.79% over the same period. The stock’s one-month performance is similarly weak, down 7.47%, while the broader market has advanced by nearly 1%. Year-to-date, the stock has fallen 4.25%, whereas the Sensex has risen by over 9%. Over the past year, the stock has underperformed significantly, delivering a negative return of 7.11% compared to the Sensex’s 10.47% gain. This persistent underperformance has weighed on investor sentiment, contributing to the recent price decline.</p>\n<p>On the day of 21-Nov, the stock underperformed its sector by 1.44%, touching an intraday low of ₹1,050.25, d..."
      }
    ],
    "total": 355,
    "sid": "525933",
    "stock_news_url": "https://www.marketsmojo.com/news/jubilant-pharmova-525933"
  },
  "announcements": [
    {
      "caption": "Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares",
      "datetime": "02-Dec-2025",
      "details": "Report on Special Window for Re-lodgement of Transfer Requests of Physical Shares",
      "source": "BSE"
    },
    {
      "caption": "Appointment Of Mr. Daniel J. OConnor As CEO Of Jubilant Therapeutics Inc.",
      "datetime": "02-Dec-2025",
      "details": "Appointment of Mr. Daniel J. O Connor as CEO of Jubilant Therapeutics Inc.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "28-Nov-2025",
      "details": "Special window for re-lodgement and KYC Updation",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has declared <strong>500%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has announced <strong>1:5</strong> stock split, ex-date: 17 Mar 06",
          "dt": "2006-03-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Jubilant Pharmo technically bullish or bearish?

2025-12-04 08:29:15

Technical Trend Shift and Current Price Action

As of 3 December 2025, Jubilant Pharmo's technical trend transitioned from mildly bullish to sideways, signalling a pause in directional momentum. The stock closed at ₹1,077.90, down from the previous close of ₹1,095.45, with intraday trading ranging between ₹1,071.40 and ₹1,098.20. This price action suggests a consolidation phase after recent volatility, with the stock currently trading below its 52-week high of ₹1,263.90 but comfortably above its 52-week low of ₹823.70.

Mixed Technical Indicators Paint a Complex Picture

Examining key technical indicators reveals a blend of bearish and mildly bullish signals. The Moving Average Convergence Divergence (MACD) on both weekly and monthly charts remains...

Jubilant Pharmova Technical Momentum Shifts Amid Mixed Market Signals

2025-12-04 08:06:47

Jubilant Pharmova’s stock price has experienced a notable shift in momentum, reflecting a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a sideways movement. This development comes amid a backdrop of mixed signals from key technical parameters such as MACD, RSI, moving averages, and Bollinger Bands, highlighting the nuanced market assessment of the pharmaceutical and biotechnology firm.

Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Flat Financials

2025-12-04 08:04:55

Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by flat quarterly financials, subdued technical indicators, and valuation metrics that contrast with its operational performance. The pharmaceutical and biotechnology company’s stock has experienced notable underperformance relative to broader market indices, prompting a revision in its analytical perspective across key parameters including quality, valuation, financial trends, and technical outlook.

How has been the historical performance of Jubilant Pharmo?

2025-12-03 22:45:40

Revenue and Profitability Trends

Jubilant Pharmo’s net sales have shown a recovery trajectory after a notable dip in 2019. From ₹9,110.82 crores in March 2019, sales declined sharply but then steadily increased to ₹7,234.50 crores by March 2025. This rebound reflects the company’s ability to regain market traction despite earlier challenges. Operating profit margins, excluding other income, peaked at 26.49% in 2020 but experienced a decline to 16.32% by 2025, indicating some margin pressure amid rising costs.

Profit after tax (PAT) has been more volatile, with a significant loss recorded in 2023 (negative ₹77.13 crores), followed by a strong recovery to ₹836.80 crores in 2025. The PAT margin mirrored this trend, dropping to -1.04% in 2023 before rebounding to 11.63% in...

Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Sector Dynamics

2025-11-27 08:05:05

Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by technical indicators, valuation metrics, financial trends, and quality considerations. While the pharmaceutical company’s stock price shows modest gains, underlying fundamentals and sector comparisons present a complex scenario for investors navigating the Pharmaceuticals & Biotechnology space.

Jubilant Pharmova Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:06:24

Jubilant Pharmova's stock has exhibited a subtle shift in price momentum, transitioning from a sideways trend to a mildly bullish stance, reflecting nuanced changes in key technical indicators. Despite mixed signals from weekly and monthly charts, the stock’s recent price action and moving averages suggest a cautious optimism within the Pharmaceuticals & Biotechnology sector.

Jubilant Pharmova Faces Mixed Technical Signals Amid Sideways Momentum

2025-11-24 08:02:39

Jubilant Pharmova's stock price has exhibited a shift from a mildly bullish trend to a sideways momentum, reflecting a complex interplay of technical indicators. Recent market data reveals a nuanced picture for this Pharmaceuticals & Biotechnology company, with key metrics such as MACD, RSI, and moving averages signalling a cautious stance for investors.

Jubilant Pharmova’s Market Assessment Reflects Mixed Signals Amidst Sector Challenges

2025-11-24 08:02:28

Jubilant Pharmova’s recent market evaluation reveals a nuanced picture shaped by shifts in technical indicators, valuation metrics, financial trends, and overall quality parameters. Despite a discount in valuation relative to peers and a solid institutional investor base, the company’s stock performance and financial growth patterns present a complex scenario for investors navigating the Pharmaceuticals & Biotechnology sector.

Why is Jubilant Pharmo falling/rising?

2025-11-22 00:33:11

Recent Price Movement and Market Comparison

Jubilant Pharmova’s shares have been under pressure recently, with a one-week decline of 6.20%, contrasting sharply with the Sensex’s modest gain of 0.79% over the same period. The stock’s one-month performance is similarly weak, down 7.47%, while the broader market has advanced by nearly 1%. Year-to-date, the stock has fallen 4.25%, whereas the Sensex has risen by over 9%. Over the past year, the stock has underperformed significantly, delivering a negative return of 7.11% compared to the Sensex’s 10.47% gain. This persistent underperformance has weighed on investor sentiment, contributing to the recent price decline.

On the day of 21-Nov, the stock underperformed its sector by 1.44%, touching an intraday low of ₹1,050.25, d...

View All News